Florence Lerebours

4.3k citations

97 papers · 2.6k indexed · 1 hit paper · h-index 29

Impact in

Cancer Research top 1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology

Papers in

Cancer Research 48
- Breast Cancer Treatment Studies 36
- Cancer Genomics and Diagnostics 10
Oncology 63
- HER2/EGFR in Cancer Research 23
- Cancer Treatment and Pharmacology 22
- Cancer Cells and Metastasis 9

Co-authors: Ivan Bièche Rosette Lidereau M. Marty Marc Espié Jean‐Yves Pierga Sengül Tozlu Sophie Vacher François‐Clément Bidard
Journals: Journal of Clinical Oncology (16 papers)Cancer Research (13 papers)PLoS ONE (6 papers)Clinical Cancer Research (4 papers)Breast Cancer Research (4 papers)
Partner nations: France United States Spain

In The Last Decade

Florence Lerebours

92 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study 2021 · 223 citations

Peers

Countries citing papers authored by Florence Lerebours

Since Specialization

Citations

This map shows the geographic impact of Florence Lerebours's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Lerebours with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Lerebours more than expected).

Fields of papers citing papers by Florence Lerebours

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Lerebours. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Lerebours. The network helps show where Florence Lerebours may publish in the future.

Co-authors

The 25 scholars most cited alongside Florence Lerebours, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Florence Lerebours Line = papers co-authored together Florence Lerebours links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract PO1-03-05: Tolerance of adjuvant radiotherapy combined with pembrolizumab for triple negative breast cancer Cancer Research ·Youlia Kirova, Thaïs Tison, Pierre Loap, Emilie Arnaud, Kim Cao, Solène Bringer, Manon Kissel, Safia Maaradji, Juliette Mainguené, Jean‐Yves Pierga, Florence Lerebours, Anne Vincent‐Salomon, Mariana Mirabelle, Delphine Loirat, François‐Clément Bidard	2024	0
2	Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer European Journal of Nuclear Medicine and Molecular Imaging ·Romain‐David Seban, Laurence Champion, Alexandre De Moura, Florence Lerebours, Delphine Loirat, Jean‐Yves Pierga, Lounes Djerroudi, Thomas Genevée, Virginie Huchet, Nina Jehanno, François‐Clément Bidard, Irène Buvat	2024	2
3	Abstract P5-02-19: ctDNA as dynamic marker of response to fulvestrant and everolimus in CDK4/6 inhibitor-pretreated ER+ HER2- metastatic breast cancer patients: a prospective study Cancer Research ·Antoine Vasseur, Caroline Hego, Wissam Taka, Olfa Trabelsi‐Grati, Florence Lerebours, Jean‐Yves Pierga, Delphine Loirat, Etienne Brain, Paul Cottu, Marie‐Paule Sablin, Luc Cabel, Benjamin Renouf, Shufang Renault, François‐Clément Bidard	2023	1
4	Sustainable return to work among breast cancer survivors Cancer Medicine ·Garazi Ruiz de Azua, Isabelle Kousignian, Inês Vaz-Luís, Antonio Di Meglio, Elsa Caumette, Julie Havas, Élise Martin, Anne‐Laure Martin, Ophélie Querel, Laurence Vanlemmens, Barbara Pistilli, Charles Coutant, Paul Cottu, Asma Dhaini Mérimèche, Florence Lerebours, Olivier Trédan, Christelle Jouannaud, Christelle Levy, Agnès Dumas, Gwenn Menvielle	2023	6
5	Coffee and tea consumption, patient‐reported, and clinical outcomes in a longitudinal study of patients with breast cancer Cancer ·Davide Soldato, Julie Havas, Tracy E. Crane, Daniele Presti, Pietro Lapidari, Nathalie Rassy, Barbara Pistilli, Élise Martin, Lucia Del Mastro, Anne‐Laure Martin, Alexandra Jacquet, Charles Coutant, Paul Cottu, Asma Dhaini Mérimèche, Florence Lerebours, Olivier Trédan, Laurence Vanlemmens, Fabrice André, Inês Vaz-Luís, Antonio Di Meglio	2022	3
6	Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer The Breast ·Pietro Lapidari, Arnauld Gbenou, Julie Havas, Élise Martin, Barbara Pistilli, Anne‐Laure Martin, Sibille Everhard, Charles Coutant, Paul Cottu, A. Lesur, Florence Lerebours, Olivier Trédan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Fabrice André, Inês Vaz-Luís, Antonio Di Meglio	2021	3
7	Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy PLoS ONE ·Anne‐Sophie Hamy, Lauren Darrigues, Enora Laas, Diane De Croze, Lucian Topciu, Giang-Thanh Lam, Clémence Evrevin, Sonia Rozette, Lucie Laot, Florence Lerebours, Jean‐Yves Pierga, Marie Osdoit, Matthieu Faron, Jean-Guillaume Féron, Marick Laé, Fabien Reyal	2020	53
8	Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials British Journal of Cancer ·Florence Lerebours, Marina Pulido, Emmanuelle Fourme, Marc Debled, Véronique Becette, Hervé Bonnefoi, Sofía Rivera, Gaëtan MacGrogan, Marie‐Ange Mouret‐Reynier, C. Tunon de Lara, Jean‐Yves Pierga, C. Breton-Callu, Laurence Venat‐Bouvet, Simone Mathoulin-Pélissier, Thibault De La Motte Rouge, Florence Dalenc, Brigitte Sigal, Thomas Bachelot, Jérôme Lemonnier, Nathalie Quénel-Tueux	2020	13
9	Bouffées de chaleur et cancer du sein avec récepteurs hormonaux positifs : mécanismes et prise en charge Bulletin du Cancer ·Iphigénie Cavadias, Roman Rouzier, Florence Lerebours, Delphine Héquet	2020	3
10	Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Clinical Cancer Research ·Anne‐Sophie Hamy, Hélène Bonsang‐Kitzis, Diane De Croze, Enora Laas, Lauren Darrigues, Lucian Topciu, Emmanuelle Menet, Anne Vincent‐Salomon, Florence Lerebours, Jean‐Yves Pierga, Étienne Brain, Jean-Guillaume Féron, Gabriel Benchimol, Giang-Thanh Lam, Marick Laé, Fabien Reyal	2019	50
11	An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress? Chinese Journal of Cancer Research ·Liang Xu, Huiping Li, Florence Coussy, Céline Callens, Florence Lerebours	2019	8
12	Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer Breast Cancer Research ·Liang Xu, Sophie Vacher, Anaïs Boulai, Virginie Bernard, Sylvain Baulande, Mylène Bohec, Ivan Bièche, Florence Lerebours, Céline Callens	2018	57
13	18F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer European Journal of Nuclear Medicine and Molecular Imaging ·Laurence Champion, Florence Lerebours, P. Chérel, Véronique Edeline, Anne‐Laure Giraudet, Myriam Wartski, Dominique Bellet, Jean‐Louis Alberini	2013	28
14	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study The Lancet Oncology ·Jean‐Yves Pierga, Thierry Petit, T. Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe‐Jauffret, Maria Pavlyuk, Sandrine Kraemer, François‐Clément Bidard, Patrice Viens	2012	113
15	Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification PLoS ONE ·Fabien Reyal, C. Bélichard, Roman Rouzier, E. De Gournay, Claire Sénéchal, François‐Clément Bidard, Jean‐Yves Pierga, Paul Cottu, Florence Lerebours, Youlia Kirova, Jean-Guillaume Féron, Virginie Fourchotte, Anne Vincent‐Salomon, Jean‐Marc Guinebretière, Brigitte Sigal‐Zafrani, Xavier Sastre‐Garau, Yann De Rycke, Charles Coutant	2012	17
16	Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study European Journal of Nuclear Medicine and Molecular Imaging ·Nina Jehanno, Anne‐Laure Giraudet, Laurence Champion, Florence Lerebours, Elise Le Stanc, Véronique Edeline, Olivier Madar, Dominique Bellet, A Pecking, Jean‐Louis Alberini	2011	47
17	18F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT) imaging in the staging and prognosis of inflammatory breast cancer Cancer ·Jean‐Louis Alberini, Florence Lerebours, Myriam Wartski, Emmanuelle Fourme, Elise Le Stanc, É. Gontier, Olivier Madar, P. Chérel, A. Pecking	2009	94
18	DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy Clinical Cancer Research ·Oliver Hartmann, Frédérique Spyratos, Nadia Harbeck, Dimo Dietrich, Anne Faßbender, Manfred Schmitt, Serenella Eppenberger‐Castori, Vincent Vuaroqueaux, Florence Lerebours, Katrin Welzel, Sabine Maier, Achim Plum, Stephan Niemann, John A. Foekens, Ralf Lesche, John W.M. Martens	2008	79
19	Molecular Profiling of Inflammatory Breast Cancer Clinical Cancer Research ·Ivan Bièche, Florence Lerebours, Sengül Tozlu, Marc Espié, M. Marty, Rosette Lidereau	2004	188
20	Evidence of chromosome regions and gene involvement in inflammatory breast cancer International Journal of Cancer ·Florence Lerebours, Philippe Bertheau, Ivan Bièche, Keltouma Driouch, Hugues de Thé, K. Hacène, Marc Espié, M. Marty, Rosette Lidereau	2002	24

About Florence Lerebours

Florence Lerebours is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 97 papers that have together received 2.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (36 papers), Advanced Breast Cancer Therapies (26 papers), HER2/EGFR in Cancer Research (23 papers), Cancer Treatment and Pharmacology (22 papers), Breast Lesions and Carcinomas (12 papers), Cancer Genomics and Diagnostics (10 papers), Cancer Cells and Metastasis (9 papers) and Estrogen and related hormone effects (8 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.4k citations), Pulmonary and Respiratory Medicine (692 citations), Pathology and Forensic Medicine (304 citations) and Genetics (162 citations). Florence Lerebours has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Ivan Bièche, Rosette Lidereau, M. Marty, Marc Espié, Jean‐Yves Pierga, Sengül Tozlu, Sophie Vacher, François‐Clément Bidard, Jean‐Louis Alberini and Roman Rouzier. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, PLoS ONE, Clinical Cancer Research and Breast Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact